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Abstract: Over the past two to three decades, gallium compounds have gained importance 
in the fields of medicine and electronics. In clinical medicine, radioactive gallium and 
stable gallium nitrate are used as diagnostic and therapeutic agents in cancer and disorders 
of calcium and bone metabolism. In addition, gallium compounds have displayed   
anti-inflammatory and immunosuppressive activity in animal models of human disease 
while more recent studies have shown that gallium compounds may function as 
antimicrobial agents against certain pathogens. In a totally different realm, the chemical 
properties of gallium arsenide have led to its use in the semiconductor industry. Gallium 
compounds, whether used medically or in the electronics field, have toxicities. Patients 
receiving gallium nitrate for the treatment of various diseases may benefit from such 
therapy, but knowledge of the therapeutic index of this drug is necessary to avoid clinical 
toxicities. Animals exposed to gallium arsenide display toxicities in certain organ systems 
suggesting that environmental risks may exist for individuals exposed to this compound in 
the workplace. Although the arsenic moiety of gallium arsenide appears to be mainly 
responsible for its pulmonary toxicity, gallium may contribute to some of the detrimental 
effects in other organs. The use of older and newer gallium compounds in clinical 
medicine may be advanced by a better understanding of their mechanisms of action, drug 
resistance, pharmacology, and side-effects. This review will discuss the medical 
applications of gallium and its mechanisms of action, the newer gallium compounds and 
future directions for development, and the toxicities of gallium compounds in current use. 
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1. Introduction 
 
Gallium is a group IIIA metal, atomic number 31 in the periodic table of elements. First discovered 
in 1875 by Paul-Emile Lecoq de Boisbaudran in France, the name of this metal appears to be derived 
from “Gallia”, the Latin word for France. However, it is also thought that perhaps the discoverer 
Lecoq named the metal after himself by calling it gallum, the Latin translation for a cock. Gallium is 
present at a concentration of 5–15 mg/kg in the earth’s crust and is obtained as a byproduct from the 
extraction of aluminum and zinc ores [1]. It has a shiny, silvery-white color, with a melting 
temperature of 28.7646 
oC (85.5763 
oF); it is one of the few metals that is near-liquid at room 
temperature and can melt when held in the hand. Although gallium has no known physiologic function 
in the human body, certain of its characteristics enable it to interact with cellular processes and 
biologically important proteins, especially those of iron metabolism. This has led to the development 
of certain gallium compounds as diagnostic and therapeutic agents in medicine especially in the areas 
of metabolic bone disease, cancer, and infectious disease. The discovery that gallium displayed 
semiconducting properties led to its development as gallium arsenide for use in the electronics industry 
[2]. In the USA, more than 95% of gallium consumed is for optoelectronic devices and integrated 
circuits [1]. The application of gallium in medicine raises questions about the pharmacology, clinical 
efficacy, and potential   
side-effects of gallium compounds as drugs. The use of gallium arsenide in the electronics industry 
raises questions about the potential risks of exposure to this compound as an environmental toxin. The 
reader is also referred to earlier reviews on gallium [3-8]. The present review will provide an update of 
the medical applications of gallium and the toxicities of gallium compounds in medicine and the 
electronics industry. 
 
2. Medical Applications of Gallium Compounds 
 
2.1. Radiogallium Compounds as Tumor Imaging Agents 
 
Early studies demonstrated that radioactive gallium (
67Ga citrate) injected into tumor-bearing 
animals localized in malignant cells [9]. This observation led to the development of the 
67Ga scan for 
the detection of malignant tumors in patients [10]. Over the past two decades, 
67Ga scanning has been 
used most frequently in patients with Hodgkin’s and non-Hodgkin’s lymphomas to detect residual 
disease or disease that has relapsed following treatment with chemotherapy or radiotherapy [11-14]. 
The level of 
67Ga incorporation into lymphoma cells reflects the metabolic activity of the tumor and is 
indicative of the presence of viable malignant cells. Hence, a positive 
67Ga scan after treatment of 
lymphoma generally indicates the presence of residual malignancy and the need for further therapy. 
The intensity of 
67Ga uptake by malignancies such as lymphoma correlates with their proliferative rate; Int. J. Environ. Res. Public Health 2010, 7          
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67Ga scanning thus provides a valuable insight into the aggressiveness of a tumor [12]. Gallium may 
also be taken up by macrophages and thus, areas of inflammation may show 
67Ga-positivity on the 
67Ga scan. Recently, the 
67Ga scan in lymphoma has been replaced by the Positron Emission 
Tomography (PET) scan which is based on the uptake of 
18F-fluorodeoxyglucose (FDG) by tumors 
[15]. However, the 
67Ga scan remains an important diagnostic modality in geographical locations 
where the 
18F-FDG PET scan may not be available. 
Although tumor imaging with 
18F-FDG PET is now being increasingly used for a variety of 
malignancies, it has its limitations. Tumors with a low growth rate such as hepatocellular carcinoma, 
neuroendocrine tumors, prostate cancer, and indolent (slow-growing) lymphomas may not take up 
FDG. Conversely, tumors surrounded by or adjacent to normal tissue with high metabolic activity 
(such as the brain) may be difficult to assess by 
18F-FDG PET because of high background FDG 
uptake by the normal tissue (i.e., a low ratio of tumor/normal tissue FDG uptake). As a result of these 
limitations, there has been considerable interest in the development of 
68Ga-labeled 
radiopharmaceuticals for molecular tumor imaging (reviewed in references 16 and 17). This gallium 
isotope has a short half-life of approximately 68 minutes which is an advantage to its clinical use. 
Peptides labeled with radiometals are showing promising clinical activity as imaging agents for the 
diagnosis and management of neuroendocrine tumors, neural crest tumors (pheochromocytomas and 
paragangliomas), meningiomas, and prostate cancer. Somatostatin, which targets the somatostatin 
receptor subtypes present in increased numbers on these cells, has been the most developed model for 
synthetic peptides. The somatostatin analogue D-Phe
1-Tyr
3-octreotide (TOC) coupled to the 
bifunctional chelate DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-teraacetic acid) labeled with 
68Ga (
68Ga-DOTATOC) has been used with great success for the imaging of neuroendocrine tumors in 
patients. In other studies, 
68Ga-DOTA-D-Phe
1-Tyr3-Thr8-octreotide (
68Ga-DOTA-TATE) PET was 
used to image the somatostatin receptor in recurrent pheochromocytoma and meningiomas in patients 
and in the latter disease led to changes in radiotherapy planning. Imaging of neuroendocrine tumors 
with another somatostatin analogue, 
68Ga-DOTANOC has also shown promise [18], while   
68Ga-DOTA-alpha melanocyte-stimulating hormone analog has been used for imaging metastases in 
melanoma [19]. In addition 
68Ga labeled-DOTA coupled to bombesin (
68Ga-DOTA-BOM) PET has 
been used to diagnose prostate cancer expressing the bombesin receptor, while 
67Ga- and 
68Ga-
deferoxamine (DFO)-folate have been used to image tumors that express high levels of cell surface 
folate receptors in a tumor xenograft model [20,21].  
2.2. Antineoplastic Activity of Gallium Nitrate in Cancer Treatment  
The ability of 
67Ga to localize in tumor cells prompted investigators at the National Cancer Institute 
(NCI) to investigate the antineoplastic activities of salts of the group IIIa metals aluminum, gallium, 
indium, and thallium in tumor-bearing CDF1 mice and Sprague-Dawley rats [22]. Of these metal 
compounds, gallium nitrate proved to be both highly effective in suppressing the growth of 
subcutaneously implanted tumors and least toxic. As a result, it was advanced to NCI investigational 
drug status (NSC 15200) for assessment of toxicity and antitumor efficacy in Phase 1 and Phase 2 
clinical trials [23]. In those clinical studies, gallium nitrate was administered by two different Int. J. Environ. Res. Public Health 2010, 7          
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schedules: a brief (15–30 minutes) intravenous infusion or a continuous intravenous infusion given 
over 24 hours for 5 to 7 days.  
While the clinical efficacy of continuous infusion gallium nitrate has been examined in a number of 
different malignancies, this drug has displayed its strongest antineoplastic activity in the treatment of 
non-Hodgkin’s lymphoma and bladder cancer. At least 4 separate clinical trials have demonstrated the 
anti-lymphoma activity of gallium nitrate administered as a single agent [24-27], while 3 additional 
trials have used it in combination with other antineoplastic agents to improve treatment   
outcome [28-30]. In all these studies, gallium nitrate was assessed in patients with relapsed   
non-Hodgkin’s lymphoma that failed to respond to many conventional chemotherapeutic drugs and 
also to stem cell transplantation. Overall, studies indicate that approximately 30% of patients with 
relapsed lymphomas will responded to treatment with gallium nitrate. Interestingly, aggressive large 
cell and mantle cell lymphomas appear to be more responsive to gallium nitrate than other lymphoma  
subtypes [27]. The activity of gallium nitrate in advanced bladder cancer has also been confirmed in 
several clinical studies. At least three studies have demonstrated an overall response in 17–63% of 
patients treated with single agent gallium nitrate [31-33], while three additional studies using gallium 
nitrate in combination with other drugs have shown overall response rates of 12–67% [34-36]. The 
12% response rate was seen in a study that combined gallium nitrate with fluorouracil [36]. This low 
response is surprising given the higher responses seen in other studies; it raises the question as to 
whether this was the result of drug antagonism between fluorouracil and gallium nitrate. An advantage 
of gallium nitrate is that unlike many chemotherapeutic drugs, it does not produce myelosuppression 
and can therefore be used in patients with low white blood cell or platelet counts. In vitro, gallium has 
shown to be synergistic with hydroxyurea, fludarabine, interferon-alpha, gemcitabine, and paclitaxel, 
suggesting that combination therapy with these agents may be fruitful [37-41]. Moreover, gallium 
nitrate does not appear to share cross-resistance with conventional chemotherapeutic drugs since 
clinical responses have been noted in patients who have failed to respond to multiple other drugs. 
2.3. Effects of Gallium Nitrate on Malignancy-Associated Hypercalcemia and Bone Metabolism 
Studies examining the antineoplastic activity of gallium nitrate revealed that a decrease in blood 
calcium levels occurred in a significant number of patients being treated with this agent [26]. Based on 
this observation, further investigations were pursued to examine the potential of gallium nitrate as a 
treatment for elevated blood calcium levels associated with cancer [42]. The bisphosphonate drugs 
have had an established role in the treatment of hypercalcemia and osteoporosis; randomized clinical 
trials were therefore conducted to compare the efficacy of gallium nitrate with the bisphosphonates 
etidronate and pamidronate in the treatment of hypercalcemia in cancer patients [43,44]. These studies 
demonstrated continuous infusion gallium nitrate (200 mg/m
2/day for 5 days) to be superior to 
etidronate and at least as effective as pamidronate in acutely controlling elevated blood calcium levels. 
Gallium nitrate was also shown to be superior to calcitonin, a non-bisphosphonate drug used for 
treatment of hypercalcemia [45]. Based on its clinical efficacy, gallium nitrate (Ganite™) was 
approved by the Food and Drug Administration (FDA) for the treatment of cancer-associated 
hypercalcemia. Zoledronic acid, a newer generation bisphosphonate, has been shown to be more potent 
than pamidronate for treatment of hypercalcemia of malignancy [46]; however, randomized trials Int. J. Environ. Res. Public Health 2010, 7          
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comparing gallium nitrate and zoledronic acid have not been conducted. Apart from its ability to 
control hypercalcemia, gallium nitrate has been shown to inhibit bone turnover and to decrease 
osteolysis in patients with multiple myeloma and in patients with bone metastases from a variety of 
different cancers [47,48]. Furthermore, administration of low, non-toxic doses of gallium nitrate to 
patients with Paget’s disease of bone, a disorder characterized by abnormal bone remodeling 
secondary to increased bone resorption by osteoclasts, led to a reduction in serum alkaline 
phosphatase, urinary hydroxyproline, and N-telopeptide, biochemical markers of bone turnover [49]. 
2.4. Potential Application of Gallium Compounds as Immunosuppressive and Anti-Inflammatory 
Agents 
Evidence that environmental gallium per se may be immunosuppressive was provided by the 
studies of Betoulle et al. in which an aquatic system was used to show that that fish (carp) exposed to 
sublethal concentrations of gallium nitrate in the water for up to 96 hours displayed a significant 
reduction in immune parameters including immunoglobulin production, phagocyte killing ability, and 
blood leukocytes [50]. Several studies using in vitro and in vivo animal systems have shown that 
gallium compounds have immunosuppressive activity in animal models of autoimmune disease. 
Gallium nitrate has been shown to suppress experimental autoimmune encephalomyelitis and prevent 
adjuvant inflammatory arthritis through suppression of macrophage function and T-cells in rat models 
[51,52]. Other studies showed that gallium nitrate can suppress lupus and prevent cardiac allograft 
rejection in murine models [53,54]. Transferrin-gallium and gallium nitrate were shown to inhibit the 
mixed lymphocyte culture response and prolong the survival of mice with severe graft-versus-host 
disease in a murine bone marrow transplant model [55]. Despite these interesting preclinical 
observations, the immunomodulatory and anti-inflammatory properties of gallium appear to have not 
been investigated in rigorous clinical studies. Further investigations appear warranted to establish 
whether the results of these in vitro and animal studies are relevant to patients with inflammatory or 
autoimmune diseases. The potential effects of gallium on inflammation and the immune system should 
be kept in mind when gallium compounds are being used for the treatment of other conditions.  
2.5. Pharmacology  
Much of our understanding of gallium’s action on cells and its toxicity is derived from 
investigations conducted to evaluate its potential as a therapeutic agent. Insights into the pharmacology 
of gallium were provided by early studies which demonstrated that radioactive 
67Ga citrate injected 
into rabbits was transported in the circulation exclusively bound to transferrin, the transport protein for  
iron [56]. Harris and Sephton showed that the uptake of radiogallium by malignant cell lines in vitro 
could be significantly enhanced by the addition of transferrin to the culture medium [57]; the clinical 
relevance of this finding was underscored by the studies of Vallabhajosula et al. who showed that in 
the blood radiogallium binds to transferrin and is transported to tumor tissue [56]. In this respect, the 
initial transport of gallium in the blood resembles that of iron. However, whereas gallium shares 
certain properties with ferric iron [Fe(III)] with respect to ionic radius and bonding, trivalent gallium 
unlike Fe cannot be reduced to a divalent state. Nonradioactive gallium binds avidly to both metal-
binding sites on transferrin, but it does so with a 300-fold less affinity than ferric iron [58]. Under Int. J. Environ. Res. Public Health 2010, 7          
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physiologic conditions, only about one-third of circulating transferrin is occupied by iron; hence, the 
metal-binding sites of the remaining transferrin molecules are available to bind and transport gallium 
as transferrin-gallium complexes. With higher levels of gallium in the circulation, transferrin binding 
is exceeded, and gallium likely circulates as gallate, Ga(OH)
4− [3].  
Gallium pharmacokinetics have been examined in Phase-1 and -2 clinical trials in which gallium 
nitrate was administered to patients as a brief or a continuous intravenous infusion. When administered 
as an intravenous infusion over 30 minutes at doses ranging from 400–700 mg/m
2 gallium nitrate, a 
biphasic gallium urinary excretion pattern with an -phase half-life of 8.3–26 minutes and a β-phase 
half-life of 6.3–196 hours was noted [59]. The latter phase reflects its binding to transferrin in the 
circulation. Sixty-nine percent and 91% of the gallium dose administered was excreted in the urine 
during the first 24 and 48 hours, respectively [59]. Similar serum gallium disappearance curves were 
noted when higher concentrations of gallium nitrate (500–900 mg/m
2) were administered by brief 
infusion. Hydration and co-administration of mannitol with gallium nitrate increased the amount of 
gallium excreted in the urine over the first hour [60]. In contrast to the peak serum levels of gallium 
attained when gallium nitrate is administered by brief infusion, administration of gallium nitrate by 
continuous intravenous infusion at its currently recommended dose of 200 mg/m
2/day for 7 days 
results in a steady-state plasma gallium level of 0.9–1.9 µg/ml which decreases to 0.45–0.7 µg/ml at 4 
days after stopping the drug. The continuous intravenous infusion schedule for gallium nitrate has 
much less toxicity than the brief infusion schedule and allows patients to receive twice the amount of 
gallium. 
2.6. Mechanisms of Action  
2.6.1. Bone metabolism 
The mechanisms of action of gallium nitrate on bone are distinct from those of bisphosphonates. 
Gallium, at non-toxic concentrations in a dose-dependent manner, accumulates in the metaphysis and 
diaphysis of bone at the interface of the organic (collagen) and the mineral components, thus altering 
crystal solubility and rendering bone more resistant to resorption (reviewed in reference 61). 
Significant increases in bone calcium content occur in gallium-treated bone which also makes bone 
less likely to be resorbed. In addition, gallium acts by blocking osteoclast activity without affecting the 
viability of these cells [61]. Osteoclasts play a critical role in bone resorption, modeling, and 
remodeling [62]. In the rat osteoclast-like cell line, gallium nitrate reduced vitamin D3-stimulated 
osteocalcin and osteopontin mRNA levels [63] and increased type 1 collagen and fibronectin 
expression in bone and fibroblast cells [64]. Collectively, studies indicate that while gallium nitrate is 
an effective drug for lowering pathologically elevated blood calcium levels in cancer, it may also have 
a broader application in diseases associated with increased bone loss such as osteoporosis, bone 
metastases, multiple myeloma, and Paget’s disease of the bone. Presently, gallium nitrate needs to be 
given to patients by continuous intravenous administration which is cumbersome and inconvenient. 
However, an oral formulation of this drug that appears promising is being advanced in early   
clinical trials [65].  
 Int. J. Environ. Res. Public Health 2010, 7          
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2.6.2. Antineoplastic activity 
Several investigations have shown that gallium is taken up by various malignant cells in vitro 
through cell surface transferrin receptor-mediated endocytosis of Ga-transferrin complexes [66-69]. 
Evidence for a role for the transferrin receptor in gallium uptake was also provided by studies showing 
that the uptake of 
67Ga by leukemic cells in vitro and by melanoma tumor in a rodent model could be 
blocked by monoclonal antibodies against the transferrin receptor [67,70]. In addition to transferrin 
receptor-facilitated uptake, a certain amount of gallium may be incorporated into cells through 
transferrin-independent mechanisms [67,69,71]. Hence, both transferrin receptor-dependent and   
-independent pathways for gallium uptake exist, and it is conceivable that their relative contributions 
to gallium uptake may vary with cell type. 
The mechanisms of antineoplastic activity of gallium are complex and can be viewed as a two-step 
process in which the first step involves the targeting of gallium (as transferrin-gallium) to transferrin 
receptor-bearing tumor cells. Indeed, the high expression of transferrin receptors known to be present 
on lymphomas and bladder cancer cells may explain, in part, the preferential sensitivity of these 
malignancies to treatment with gallium nitrate [72-75]. In the second step, gallium perturbs cellular 
iron metabolism by interfering with transferrin receptor-mediated uptake of iron and with the 
endosomal release of iron from transferrin to the cytoplasm [76]. This leads to a condition of relative 
cellular iron deprivation and inhibition of the iron-dependent function of ribonucleotide reductase, the 
enzyme essential for deoxyribonucleotide synthesis [37]. Ribonucleotide reductase is a heterodimer 
protein consisting of R1 and R2 subunits; the R2 subunit contains a binuclear iron center and a tyrosyl 
free radical that are essential for enzyme function [77]. Perturbation of cellular iron homeostasis by 
gallium limits iron availability for R2 activity thus blocking ribonucleotide reductase activity and 
consequently DNA synthesis [37,78]. In addition, gallium has been shown to directly inhibit 
ribonucleotide reductase enzyme activity in cell lysates [79]; this indicates that gallium inhibits 
deoxyribonucleotide synthesis by dual mechanisms: a blockade of intracellular iron trafficking to the 
enzyme and a direct action on the enzyme that is independent of iron transport.  
Recent studies have provided additional insights into the mechanisms of gallium-induced cell death 
in lymphoma. Gallium nitrate and gallium maltolate, a new gallium compound, induce apoptosis in 
human lymphoma cell lines through an intrinsic mitochondrial pathway that involves the activation of 
proapoptotic Bax, loss of mitochondrial membrane potential, release of cytochrome c from the 
mitochondria, and the activation of caspase-3 [80,81]. Exposure of human lymphoma CCRF-CEM 
cells to gallium nitrate results in the generation of reactive oxygen species (ROS) and a decrease in the 
GSH/GSSG ratio within 4 hours of incubation, long before any loss of cell viability occurs. This is 
followed by an induction of metallothionein-2A and heme oxygenase-1 expression which can be 
inhibited by the antioxidant N-acetyl cysteine [82]. In addition, gallium exposure leads to 
phosphorylation of p38 mitogen-activated protein kinase and the activation of Nrf-2, a transcription 
factor for heme oxygenase-1 [82]. These results suggest a model in which gallium nitrate-induced 
ROS production initially leads to a cytoprotective response (induction of metallothionein and heme 
oxygenase-2 production) and that cell death ensues when this protective response is overwhelmed. A 
protective role for metallothionein-2A against the growth-inhibitory effects of gallium nitrate is also 
suggested by experiments that show that zinc-induced upregulation of metallothionein diminishes the Int. J. Environ. Res. Public Health 2010, 7          
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cytotoxicity of gallium in CCRF-CEM cells and that this protection decreases as metallothionein levels 
return to baseline [83].  
Additional cellular processes may be altered by gallium. Protein tyrosine phosphatase inhibition by 
gallium nitrate has been demonstrated in Jurkat and HT-29 human colon cancer cells, but a correlation 
between enzyme inhibition and cell proliferation was not found [84]. Gallium can inhibit magnesium-
dependent ATPase through competition with magnesium [85], and GaCl3 can inhibit tubulin 
polymerization, an effect that could contribute to its antineoplastic activity [86]. Early studies showed 
that DNA polymerases were partially inhibited by gallium nitrate; however, the extent of inhibition 
was insufficient to account for gallium’s antitumor activity [87]. In prostate cancer cell lines and a 
xenograft model, the proteasome was recently reported to be a target for the action of a new group of 
gallium compounds consisting of gallium complexed to ligands containing pyridine and 4-6-
substituted phenolic moieties [88]. All these effects of gallium are of interest, and their contributions to 
the antineoplastic activity of gallium warrant further investigation. 
 
2.6.3. Drug resistance 
Drug resistance to antineoplastic agents remains a major obstacle to the successful treatment of 
cancer. The basis for tumor cell resistance to gallium nitrate is not well understood, and CCRF-CEM 
lymphoma and HL60 human leukemia cell lines with an acquired resistance to gallium nitrate have 
been developed as tools to investigate the underlying mechanisms for this resistance. In HL60 cells, 
the development of resistance to growth inhibition by gallium nitrate is associated with a decrease in 
transferrin receptor-1 levels, a decrease in iron uptake, and an alteration in the intracellular trafficking 
of iron and gallium [89]. A downregulation of transferrin receptor-1 expression and gallium and iron 
uptake was seen in gallium-resistant CCRF-CEM cells [90,91]. The antiproliferative effect of gallium 
nitrate in these gallium-resistant cells could be in increased by increasing the concentration of 
exogenous transferrin in the culture medium [90,92]. These studies suggest that the development of 
gallium resistance includes changes in the uptake and intracellular transport of gallium. However, 
other processes may also be involved. Analysis of gallium-resistant and sensitive CCRF-CEM cells 
using a cDNA microarray approach that evaluated 96 genes associated with metal metabolism revealed 
a marked upregulation of metallothionein-2A, zinc transporter-1, and increased activity of metal 
responsive transcription factor-1 in cells resistant to gallium nitrate [83]. These studies suggest an 
action of gallium on proteins involved in zinc metabolism and a possible effect of metallothionein as a 
modulator of gallium sensitivity in certain cells. Metallothionein is variably expressed in different 
lymphomas in vivo [93]; therefore, a question to be addressed in future clinical trials is whether this 
expression affects the response of this malignancy to treatment with gallium compounds.  
3. Some Future Directions for the Development of Gallium Compounds in Medicine 
3.1. New Gallium Compounds with Antitumor Activity 
Gallium nitrate is a simple metal salt that can be considered to belong to a first generation of 
gallium compounds. There is considerable interest in gallium-based metallodrugs and novel gallium 
agents are in development as illustrated in Table 1. These include the oral formulations gallium Int. J. Environ. Res. Public Health 2010, 7          
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maltolate, G4544, and KP46, all of which are in clinical development [5,65,94]. Gallium maltolate 
inhibits hepatocellular carcinoma cell growth and induces apoptosis through action on the 
mitochondrial pathway in lymphoma cell lines [81,95]. On a mole-to-mole basis, this compound 
appears to be more cytotoxic to malignant cell lines in vitro than gallium nitrate. G4544 is being 
examined clinically for bone metastases and metabolic bone disease but may also prove to be active as 
an antineoplastic agent [65]. KP46 (Tris(8-quinolonato)Ga(III) is in clinical trials in Europe [96] and 
has been shown to induce apoptosis in a large panel of malignant cell lines [5,97]. In preclinical 
studies, gallium complexes of ligands containing pyridine and 4,6-substituted phenolate moieties with 
antitumor activity have been developed and have shown activity against prostate cancer xenografts in 
rats [88,98]. In addition, gallium thiosemicarbazones and novel organometallic gallium compounds are 
being aggressively advanced as therapeutic agents [99-102]. It is possible that these newer agents may 
have additional mechanisms of action that may be somewhat different from those of gallium nitrate. 
For example, gallium maltolate was recently shown to inhibit the growth of lymphoma cell lines with 
either acquired or inherent resistance to the cytotoxicity of gallium nitrate [81]. These data would 
suggest that the mechanisms of cell death induction by gallium maltolate occurs through pathways that 
are different than that for gallium nitrate [81]. The availability of lymphoma cell lines that are resistant 
to gallium nitrate-induced apoptosis provides the opportunity to examine whether the other newer 
gallium compounds share cross-resistance to gallium nitrate and whether these compounds may be 
more efficacious as therapeutic agents. The advancement of new gallium compounds to further 
preclinical and clinical testing is awaited with great anticipation. 
Table 1. Gallium Compounds in Clinical and Preclinical Development. 
Gallium Compounds  Tumors or diseases investigated/being investigated 
First Generation–FDA-approved  
Gallium nitrate [103-106]. 
 
Hypercalcemia, metabolic bone disease 
Bladder cancer, lymphoma, other cancers  
Microbial infections  
Second generation–Preclinical and Phase 1 and 2 
 clinical trials 
 Gallium maltolate [81,95,107]  
 G4544 [65] 
 Tris(8-quinolonato)Ga(III) KP46 [5;96;97] 
 
 
Hepatoma, lymphoma, microbial infections  
Metabolic bone disease, osteoporosis, skeletal metastases 
Lung cancer, melanoma, other cancers  
Third generation–Preclinical 
 Gallium thiosemicarbazones [99-101] 
 Gallium complexes with ligands of pyridine 
 & 4-6-substituted phenolic moieties [88] 
 Organometallic gallium compounds [102] 
 
Various malignant cell lines, cryptococcus fungi  
Prostate cancer (rat model) 
 
Various malignant cell lines 
3.2. Gallium Compounds as Antimicrobial Agents 
The ability of gallium to interfere with the utilization of iron by certain microorganisms has led to 
some interesting investigations directed at exploring the potential of gallium as an antimicrobial drug. 
Gallium nitrate and transferrin-gallium were shown to block the iron-dependent growth of 
Mycobacterium tuberculosis and M. avium complex extracellularly as well as within human Int. J. Environ. Res. Public Health 2010, 7          
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macrophages. Gallium interfered with iron acquisition by M. tuberculosis within the macrophage 
phagosome resulting in a bactericidal action which could be prevented by excess iron [108]. In another 
study, gallium nitrate inhibited Pseudomonas aeruginosa growth and biofilm formation, and killed 
planktonic and biofilm bacteria in vitro through mechanisms that included interference with iron 
uptake and iron signaling by the transcription regulator pvdS. In this study, gallium was effective 
against P. aruginosa pneumonia in mice and prolonged their survival [106]. In a mouse model of 
thermal injury inoculated with P. aeruginosa, gallium maltolate provided a 100% survival compared 
with 100% mortality in control mice not treated with gallium [107]. Patients with cystic fibrosis often 
develop Pseudomonas lung infections that may be resistant to standard antibiotics and difficult to 
eradicate; a clinical trial is in progress to assess the efficacy of gallium nitrate in the treatment of lung 
infections in this patient population (Genta Incorporated Inc; Press release December 2, 2009). 
4. Challenges to Advancing Gallium Compounds as Therapeutic Agents in the Clinic 
Gallium nitrate is presently approved for use in the clinic; however, for optimal efficacy, this drug 
needs to be administered by continuous intravenous infusion 24-hours a day for 5–7 days. This is 
obviously a cumbersome mode of treatment. It would be highly desirable to have gallium compounds 
that could be administered orally and have at least equivalent (or greater) therapeutic efficacy than 
intravenous gallium nitrate. Hence, there is a great need to continue to develop such agents, establish 
their therapeutic index (efficacy to toxicity ratio) in preclinical studies and advance them to human 
trials. At the same time, further research is needed to understand the molecular targets of gallium and 
its mechanisms of action. Clinical experience with gallium nitrate has shown that some patients with 
lymphoma resistant to conventional chemotherapy have responded dramatically to a single course of 
treatment whereas others have responded only partially or not at all [29,109]. This begs the question as 
to why certain cancers are inherently resistant to gallium while others are exquisitely sensitive. An 
understanding of the basis of drug resistance to gallium may allow us to use molecular markers in 
tumors to identify patients most likely to benefit from gallium-based treatment and to design newer 
gallium compounds that could bypass such resistance.  
5. Toxicities of Gallium Compounds in Current Use 
5.1. Gallium Nitrate 
Treatment with continuous intravenous infusion gallium nitrate at the present recommended dose 
for hypercalcemia (200 mg/m
2/day for 5 days) is generally well-tolerated, even by elderly patients. 
Higher continuous infusion doses (300 mg/m
2/day for 5–7 days) are used for treatment of cancer. In 
phase 1 and 2 studies, renal toxicity was dose-limiting when gallium nitrate was administered as a 
brief intravenous infusion over 30 minutes [60]; this side-effect was seen in ~12.5% of patients treated 
for hypercalcemia by continuous intravenous infusion. With the continuous infusion schedule for 
treatment of lymphoma, diarrhea rather than renal toxicity was dose-limiting [26]. Renal toxicity can 
be minimized by ensuring adequate fluid intake and avoiding of coadministration of nephrotoxic 
drugs. Microcytic anemia may develop in patients treated with gallium nitrate; however, platelet 
counts and white blood cell counts are not suppressed [23]. The latter is a major advantage as it means Int. J. Environ. Res. Public Health 2010, 7          
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that unlike other chemotherapeutic drugs, gallium nitrate can be administered to patients with 
thrombocytopenia or neutropenia. Visual and auditory toxicities may occur but have been reported in 
<1% of patients. Hypocalcemia may develop in patients with normal blood calcium levels; this can be 
managed by oral supplementation with calcium carbonate. 
 
5.2. Gallium Arsenide  
Gallium arsenide is a valuable compound that is employed widely in the electronics industry. It 
possesses several advantages over silicon in that it has several-fold greater electron mobility and only 
a fraction of the electrical capacitance of silicon [110]. This property, along with its light-emitting, 
electromagnetic, and photovoltaic properties allow it to be used extensively in high-speed   
semi-conductor devices, in high power microwave and millimeter-wave devices, and in optoelectronic 
devices [1]. The latter include light-emitting diodes (LEDs), laser diodes, photodetectors and solar 
cells that are used in numerous applications.  
Workers in the microelectronics industry may be exposed to gallium arsenide during the process of 
sandblasting gallium arsenide ingots, in the slicing, grinding, and polishing of gallium arsenide-silicon 
wafers, and in clean-up of work areas [1]. For these individuals, the primary portals of entry of gallium 
arsenide into the body would be via the respiratory tract and, to a much lesser extent, the 
gastrointestinal tract. Gallium and arsenic have been shown to be elevated in ground water obtained 
from semiconductor manufacturing industrial areas, thus suggesting that contaminated drinking water 
may also be a source of environmental exposure to gallium [111]. While it is felt that the toxicities of 
gallium arsenide are related primarily to the arsenic component of this compound, the contribution of 
gallium to some of these toxicities cannot be discounted especially in light of the fact that other 
gallium compounds display antineoplastic and antimicrobial activities. Therefore, a discussion of the 
toxicities of gallium arsenide and the relative contribution of gallium to these toxicities is warranted.  
 
5.2.1. Animal studies of gallium arsenide toxicity  
An understanding of the potential risks of acute, subacute, or chronic environmental exposure to 
gallium arsenide has been gained through studies in which rats and mice were exposed to gallium 
arsenide under conditions of inhalation, intratracheal administration, or oral intake.  
 
Inhalation of gallium arsenide  
The National Toxicology Program reported the effects inhalation of gallium arsenide particles by 
F344/N rats and B6C3F1 mice produced over a period of 16 days, 14 weeks, or 2 years [112]. In the 
16-day study, animals were exposed to 0, 1, 10, 37, 75, or 150 mg/m
3 gallium arsenide inhalation,  
6 hours per day, 5 days per week for the duration of each period. At the end of the study, animal 
weights were similar to controls, and there were no deaths. The liver and lung weights were increased 
in male rats exposed to >1 mg/m
3 and in female rats and mice of both sexes exposed to >10 mg/m
3, 
while thymus weights were decreased in male rats exposed to 10 mg/m
3. Gallium arsenide particles 
were detected in the alveolar spaces and within alveolar macrophages at higher concentrations in both 
animals. Minimal histiocytic cellular infiltrate and moderate proteinosis in the lung were noted in Int. J. Environ. Res. Public Health 2010, 7          
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animals exposed to >10 mg/m
3, while laryngeal epithelial hyperplasia and squamous metaplasia were 
noted in mice and rats exposed to >10 mg/m
3 and 150 mg/m
3 gallium arsenide, respectively. Mild 
chronic inflammation was noted in mice exposed to 75 or 150 mg/m
3.  
With a 14-week inhalation exposure, rats and mice were exposed to gallium arsenide particulate at 
concentrations of 0, 0.1, 1, 10, 37, or 75 mg/m
3, 6 hours per day, 5 days per week for 14 weeks. No 
animal deaths were observed; however, final mean body weight and weight gain were significantly 
diminished in male animals compared with controls. A microcytic anemia with increased zinc 
protoporphyrin/heme ratios, increased platelet and neutrophil counts, and increased serum alanine 
aminotransferase and sorbitol dehydrogenase was noted. In males, testicular toxicity was noted at the 
higher concentrations of gallium arsenide that was characterized by a decrease in weights of the testes, 
cauda epididymis, and epididymis. Testicular atrophy was seen at the highest concentration of gallium 
arsenide in male rats, while total spermatid heads, spermatid counts, and spermatic motility were 
significantly decreased at lower concentrations. Increases in the incidence of plasma cell hyperplasia 
of mandibular lymph notes, bone marrow hyperplasia, and hemosiderosis of the liver and spleen were 
observed with the higher concentrations of gallium arsenide. The pulmonary toxicity noted with 
gallium arsenide inhalation for 14 weeks was an extension of that seen with a 16-day exposure. Lung 
weights were increased; proteinosis, histiocytic infiltration, and epithelial hyperplasia in the lung 
accompanied by inflammation and squamous metaplasia in the larynx were observed with the higher 
concentrations of gallium arsenide. 
In a 2-year study of gallium arsenide inhalation exposure, B6C3F1 mice were exposed to 0, 0.1, 
0.5, or 1.0 mg/m
3 gallium arsenide for 6 hours a day, 5 days per week for 105 weeks (males) or 106 
weeks (females). This resulted in a spectrum of inflammatory and proliferative lesions in the 
respiratory tract without the development of cancer. In another study, male and female Fischer 344/N 
rats were exposed to inhalation of 0–1 mg/m
3 of gallium arsenide particles for 6 hours per day, 5 days 
a week for 105 weeks. Although there was no adverse impact on survival, inflammatory lesions, 
atypical hyperplasia, and metaplasia in the respiratory tract were noted. Particles of gallium arsenide 
were detected in the alveolar spaces and macrophages in animals exposed to the higher concentrations 
of this compound [112]. In addition to displaying a spectrum of such changes in the lung, female but 
not male rats had a gallium arsenide concentration-dependent increase in benign and malignant lung 
lesions (alveolar/bronchiolar, adeno, and squamous cell carcinomas). Females also had a gallium 
arsenide concentration-dependent increase in adrenal neoplasms, and an increased incidence of large 
granular lymphocytic leukemia with exposure to 1.0 mg/m
3 of this compound.  
 
Intratracheal administration of gallium arsenide  
The toxicities of gallium arsenide administered by intratracheal installation to rodents using various 
schedules ranging from a single dose to repetitive exposure are summarized in the studies in Table 2. 
Details of these and related studies have been presented in recent reviews [1,113]. As with inhalation 
exposure, intratracheal installation of gallium arsenide produces various levels of damage to the 
respiratory tract. In addition, as shown in Table 2, this mode of gallium arsenide delivery may also 
produce testicular toxicity, inhibition of the heme biosynthetic pathway, decreases in hemoglobin 
levels, renal damage, and suppression of immunological functions.  Int. J. Environ. Res. Public Health 2010, 7          
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Table 2. Toxicities of Intratracheal Installation of Gallium Arsenide (GaAs) in Animals. 
Organ systems and animals  Outcome 
Pulmonary  
Male Fischer-344 rats; single installation of 
10, 30, or 100 mg/kg GaAs; analysis at   
14 days [114] 
 
Male Fischer-344 rats; single installation of 
100 mg/kg GaAs; analysis at 14 days [115] 
 
 
Male Fischer-344 rats; single installation of 
smaller particle diameter “respirable”   
100 mg/kg GaAs. Analysis on days 1, 3, 7, 
14, and 28 [116] 
 
Male CD rats; single installation of 50, 100, 
or 200 mg/kg GaAs [117] 
 
Syrian golden hamsters; Installation of 0.5 
mg GaAs per week for 15 weeks,   
2 year observation [118] 
 
Syrian Golden Hamsters; 7.6 mg/kg GaAs 
twice per week x 4 weeks. Evaluated at 8 and 
16 weeks [113] 
 
Weight loss; dose-dependent increase in lung weight; 14- 42% of As and 23–42% of 
gallium dose retained in lung; arsenic, but not gallium detected in the blood; increased 
urinary excretion of porphyrins 
 
Increased weight and dry lung weight with elevation of lung protein, DNA, and 4-
hydroxyproline; pulmonary retention of GaAs particles with multifocal alveolitis, 
purulent pneumonia, Type II pneumocyte hyperplasia, necrosis, and mild fibrosis 
 
Loss of body weight, pneumocyte hyperplasia, proliferative pneumonia, interstitial 
pneumonia, perivascular cuffing, lymphoid hyperplasia, edema, fibrosis, hemorrhage, 
vascular congestion, and alveolar proteinosis 
 
 
Increased lung weight, and seropurulent pneumomia; increase in Type II pneumocytes 
and alveolar macrophases; interstitial pneumonia  
 
Reduced survival and pulmonary inflammation  
 
 
 
Moderate inflammation with diffuse alveolar bronchiolar cell hyperplasia and infiltration 
with alveolar macrophages; mild interstitial fibrosis and cholesterol clefts 
Testicular 
Syrian Golden hamsters; 7.7 mg/kg GaAs, 
twice a week for 14 installations [119]  
Rats; 7.7 mg/kg GaAs, twice a week for 14 
installations [120] 
 
Sperm count reduced by 22%, 3-fold increase in spermatid retention and degeneration, 
increase in abnormal sperm 
 
Sperm count reduced by 41%; 40-fold increase in degenerating late elongated spermatids 
Renal  
Male CD rats; single installation of 50, 100, 
or 200 mg/kg GaAs [117] 
 
Syrian Golden Hamsters [113] 
 
Mitochondrial swelling in proximal tubules 
 
 
Atrophy and degenerative changes of convoluted tubules 
 
Heme biosynthesis  
Male CD rats; single intratracheal installation 
of 50, 100, or 200 mg/kg GaAs [117] 
 
 
Dose-dependent inhibition of blood delta-aminolevulinic acid dehydratase (ALAD) in 
erythrocytes (by 3 days), and kidney (by 6 days), increased urinary ALA excretion by 6 
days 
Immunologic 
B6C3F1 mice; single intratracheal dose of 
50–200 mg/kg GaAs [121-124]. 
 
Suppression of both humoral and cell-mediated immunity; inhibition of T-cell 
proliferation; altered CD25 expression; suppression of macrophage processing of 
antigens and IgM response Int. J. Environ. Res. Public Health 2010, 7          
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Oral administration of gallium arsenide  
Two representative studies of oral gallium arsenide in animals are summarized in Table 3. With oral 
administration, the majority of gallium and arsenide appears in the feces thus indicating that this 
compound has limited bioavailability. Not surprisingly, pulmonary toxicity is not encountered with 
oral gallium arsenide; however, Flora et al. (Table 3) found a dose-dependent inhibitory effect of oral 
gallium arsenide on heme biosynthesis and primary immune response along with evidence of hepatic 
oxidative stress [125]. Collectively, animal studies show that gallium arsenide administered by 
inhalation or by intratracheal instillation is considerably more toxic than oral gallium arsenide.  
Table 3. Toxicities of Orally Administered Gallium Arsenide in Animals. 
Animals Outcome 
Male Fischer-344 rats  
Single oral dose of 10, 100, or 1000 mg/kg GaAs; 
analysis at 14 days [114]. 
 
Dose-dependent recovery of gallium (70–99%) and 
arsenic (56–91%) in the feces. Arsenic, but not 
gallium, detected in the blood. Significant increase in 
urinary uroporphyrin excretion with highest dose. No 
pathologic changes in lungs, liver, spleen, kidney, or 
testes. 
 
Male Wistar albino rats  
Single oral dose of 10, 200, or 500 mg/kg GaAs. 
Analysis at 1, 7, and 21 days [125]. 
 
Weight loss. Increased liver weight, increased serum 
gamma-glutamyltranspeptidase and serum aspartate 
aminotransferase activity, decreased hepatic 
malondialdhyde and glutathione content.  
Increased renal alkaline phosphatase activity. 
Decreased erythrocyte delta-aminolevulinic acid 
dehydratase (ALAD); increased urinary ALA and 
protein excretion. Dose-dependent decrease in spleen 
weight and cellularity, and decreased IgM production 
by antibody-forming cells in response to sheep 
erythrocytes. 
5.2.2. Human studies  
Several studies have reported on the exposure of workers to gallium arsenide and other metals in 
the optoelectronic industry in Taiwan. Liao et al. measured gallium and arsenic levels in the blood and 
urine of 4 separate groups of workers: (1) fabrication equipment preventative maintenance workers, (2) 
dopants and thin film (dope film) workers, (3) fabrication supervisors and engineers, and (4) 
nonexposed office workers. Significantly increased levels of gallium and arsenic were detected in the 
urine of the first three groups of workers exposed to gallium arsenide compared with the non-exposed 
control group [126]. The use of masks and gloves had a protective effect against gallium arsenide 
exposure indicating that this compound may be taken up by workers through the respiratory tract and 
skin [126]. In another study, Liao et al. showed that blood and urine levels of malondialdehyde 
(MDA), the byproduct of lipid peroxidation, was elevated in electronics industry workers exposed to 
aluminum, gallium, indium, and arsenic and that MDA levels strongly correlated with urinary levels of 
gallium and arsenic [127]. In an additional investigation, Chen measured metal concentrations in the Int. J. Environ. Res. Public Health 2010, 7          
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inhalable air and in the urine of workers in the workplace of two major semiconductor companies in  
Taiwan [128]. The gallium concentration in inhalable air samples from the work areas of production 
operators and engineers (exposed groups) ranged from 0.34–101.26 µg/m
3 while the urinary gallium 
levels ranged from 4.42–56.31 µg/L [128]. In contrast, gallium levels in the inhalable air and in the 
urine of control, unexposed individuals (office administrators) were 0.14–18.0 µg/m
3 and   
0.09–8.05 µg/L, respectively [128]. 
5.3. What is the Contribution of Gallium to the Toxicities of Gallium Arsenide?  
In aqueous medium, gallium arsenide rapidly dissociates to form gallium and arsenic oxides which 
may be further hydrolyzed [114]. The toxicities of arsenic are well recognized, and it has been 
suggested that the toxicities of gallium arsenide may be largely caused by the arsenic component of 
this compound [129]. However, this may be dependent on the target organ examined and on the 
conditions under which animal experiments were conducted. The following studies shed some light on 
this matter.  
 
5.3.1 Pulmonary toxicity 
Webb et al. compared the pulmonary toxicity of a single intratracheal administration of 100 mg/kg 
gallium arsenide with that of gallium trioxide (Ga2O3) and arsenic oxide (As2O3) in male Fischer-344 
rats [115]. Histopathological changes of inflammation, necrosis, neutrophil infiltration, and fibrosis 
were noted in the animals treated with gallium arsenide and As2O3. In contrast, Ga2O3-treated animals 
displayed an increase in lipid and only mild pneumomonocyte hyperplasia. Visible particles of Ga2O3, 
nodules of macrophages, and phagocytosis of these Ga2O3 particles by macrophages were also seen in 
these lungs. Hence, gallium does not appear to be a pneumotoxicant.  
 
5.3.2. Heme synthesis  
Intratracheal administration of gallium arsenide to rats results in the suppression of the heme 
synthesis pathway via inhibition of delta-aminolevulinic acid dehydratase (ALAD) in several   
tissues [117]. In a separate study that examined the effects of gallium independent of arsenic, Goering 
and Rehm showed that within 24 hours of administration, a single intraperitoneal dose of soluble 
gallium sulfate (12.5–200 mg Ga/kg) produced a dose-dependent noncompetitive inhibition of ALAD 
in the liver, kidney, and erythrocytes (inhibition constant for ALAD was approximately 3 μM  
gallium) [130]. Interestingly, the inhibitory effects of gallium on hepatic and renal ALAD was 
attenuated by zinc suggesting that gallium’s action on this enzyme may involve displacement of zinc 
from its binding to the active sulfhydryl group of the enzyme [130]. This study clearly indicates that 
gallium per se can inhibit ALAD and may thus contribute to the inhibitory effect of gallium arsenide 
on heme synthesis; however, an important factor determining this effect may be the route of entry of 
gallium into the body.  
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5.3.3. Testicular toxicity  
The available data on the effects of gallium on the testes are conflicting. Omura et al. compared the 
testicular toxicities of gallium arsenide, indium arsenide, and As2O3 in male Wistar rats receiving these 
compounds by repetitive intratracheal instillation twice a week for 16 treatments [120]. A significant 
increase in morphologically abnormal sperm, a decrease in sperm count, and an increase in 
degenerating late spermatids were seen in the gallium arsenide-treated animals. Indium arsenide 
showed much weaker testicular toxicity than gallium arsenide while no toxicity was seen with As2O3. 
It was concluded that gallium likely contributed to the testicular toxicity of gallium arsenide [120]. In 
contrast, Colombina et al. administered increasing doses of gallium nitrate to male mice 
subcutaneously every other day for 14 days and did not see an effect of gallium on fertility, 
reproduction, sperm counts, and the testes [131]. Unfortunately, there are only a limited number of 
studies examining the effect of gallium per se on the testes, so that firm conclusions regarding this 
toxicity of gallium need to be made with caution. But, it is important to note that there were 
differences in the schedule and mode of administration of gallium (intratracheal versus subcutaneous 
injection and 8 weeks versus 14 days) in these two studies. Thus, the possibility that prolonged, 
chronic exposure to gallium may produce testicular damage cannot be excluded. 
 
5.3.4. Immunosuppression  
An important toxicity of gallium arsenide is its suppressive action on the immune system.   
Sikorski et al. compared the effects of gallium arsenide and sodium arsenite on cellular and humoral 
responses in female B6C3F1 mice 14 days after the administration of a single intratracheal installation 
of either agent [132]. A differential effect of gallium arsenide and sodium arsenite on immune 
parameters was noted. The splenic IgM response to the T-dependent antigen sheep red blood cells was 
reduced by gallium arsenide in a dose-dependent manner to a 65.5% decrease at the highest dose of 
this compound (200 mg/kg); this was accompanied by a significant decrease in spleen weight and 
cellularity. In contrast, sodium arsenite decreased the splenic IgM response by 24% and did not affect 
spleen size or cellularity. The spleen cells from gallium arsenide-treated mice displayed a dose-related 
suppression of the mixed lymphocyte response (MLR) to the presence of allogeneic stimulating cells; 
in contrast, sodium arsenite-treatment not did result in suppression of the MLR [132]. Natural killer 
cell activity was increased in gallium arsenide-treated but not in sodium arsenite-treated mice. Gallium 
arsenide treatment but not sodium arsenite treatment appeared to increase the resistance of mice to 
mortality from Listeria monocytogenes infection. However, gallium arsenide but not sodium arsenite 
decreased the resistance of mice to the growth of implanted B16F10 melanoma cells [132]. 
Collectively, these studies indicate that the effects of gallium arsenide on the immune system are not 
due to arsenic alone and that gallium contributes significantly to the action of this compound.  
In a separate study however, Burns et al. examined the individual roles of gallium and arsenic on 
the immunosuppressive activity of gallium arsenide by measuring the primary antibody-forming cell 
(AFC) response of B6C3F1 mice splenocytes to sheep erythrocytes in vitro [133]. Suppression of the 
in vitro AFC IgM response was seen with gallium arsenide, gallium nitrate, and sodium arsenite. 
However, the authors concluded that arsenic was the primary contributor to the early Int. J. Environ. Res. Public Health 2010, 7          
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immunosuppressive effects of gallium arsenide based on the observations that: (1) the concentration of 
gallium required to inhibit the early IgM response was greater when gallium was added to the 
incubation as gallium nitrate than when it was added as gallium arsenide and, (2) the gallium chelator 
oxalic acid did not reverse gallium arsenide-induced IgM response [133].  
Considering the results of other studies that demonstrate that gallium compounds other than gallium 
arsenide display can suppress the immune system (discussed in Section 2.4), the collective data would 
indicate that gallium per se also contributes to the immunosuppressive action of gallium arsenide. 
6. Conclusions 
Almost 135 years after its discovery, gallium continues to show promise for the treatment of certain 
diseases. However, this potential needs to be further explored and the newer gallium compounds being 
developed should be advanced to clinical trials after rigorous preclinical testing. At the same time, 
there needs to be a better understanding of gallium’s mechanisms of antineoplastic activity and its 
molecular targets. It is envisioned at such information would enable us to identify diseases and patients 
who would selectively benefit from gallium-based therapy.  
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